Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA +62.75% EV-to-EBIT is 13.43 as of Aug. 30, 2026. The stock has 7 warning signs investors should review. Among 365 Biotechnology companies, Emmaus Life Sciences ranks better than 53.42% on this metric.
Emmaus Life Sciences (OTCPK:EMMA) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Emmaus Life Sciences's Enterprise Value for the quarter that ended in Jun. 2026 was $28.43 Mil.
Emmaus Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences EV-to-EBIT Related Terms
Emmaus Life Sciences EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Emmaus Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's EV-to-EBIT falls into.
Emmaus Life Sciences's current Enterprise Value is $33.53 Mil.
Emmaus Life Sciences's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a EV-to-EBIT of 13.43 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #170 out of 365 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Emmaus Life Sciences' EV-to-EBIT too high?
Emmaus Life Sciences' current EV-to-EBIT is 13.43. The Biotechnology industry median EV-to-EBIT is 15.95. Emmaus Life Sciences' value of 13.43 is 15.8% below this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #170 out of 365 companies in the Biotechnology industry, which is above the industry midpoint.
How does Emmaus Life Sciences' EV-to-EBIT compare to AGTX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #170 out of 365 companies for EV-to-EBIT. This puts Emmaus Life Sciences in the upper half of its industry. The industry median EV-to-EBIT is 15.95. Emmaus Life Sciences' value of 13.43 is 15.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current EV-to-EBIT of 13.43 is 15.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current EV-to-EBIT is 13.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.08 — trading 730% above its estimated fair value. The current EV-to-EBIT is 13.43 and 15.8% below the Biotechnology industry median of 15.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current EV-to-EBIT is 13.43 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
